The animal health industry has seen remarkable growth and transformation over the past decade. Beyond advances in veterinary science, innovative service models have made care more efficient, consumer friendly, and sophisticated. Many advanced treatments formerly reserved for human focused medicine are becoming increasingly accessible for companion animals. This evolution has driven pharmaceutical and veterinary care companies to leverage best-in-class talent and technology, spurring innovation across the sector. From advanced diagnostic tools and treatment methodologies to tech-enabled services and veterinary software solutions, veterinary practices and animal health companies are looking to optimize product portfolios and care delivery, improve outcomes, and enhance operational efficiency.
The industry has meanwhile experienced significant consolidation, attracting record levels of investor capital. Private equity firms and strategic buyers are actively investing in veterinary practices, diagnostics, livestock genetics, pharmaceutical services, and pet care products, recognizing the sector’s robust growth potential and resilience. At the same time, the venture capital community remains supportive of innovative companies spanning biotechnology, vaccines, compounding, reproductive technologies and food safety. This influx of capital is driving further consolidation, enabling companies to expand services, enhance capabilities, and achieve economies of scale.
At Edgemont, we help animal health and veterinary services companies capitalize on these advancements. As a leading advisor with deep expertise across the full spectrum of veterinary services, pharmaceutical, biotechnology, diagnostic, precision medicine, livestock genetics, distribution, and other veterinary technology companies, we are committed to securing superior transaction outcomes for our clients—so they can continue to deliver exceptional care and advance companion and production animal health.
Managing Director
Managing Director